Dionisia Quiroga, DO, PhD
Basic profileDionisia Quiroga is an Oncology physician affiliated with The Ohio State University Comprehensive Cancer Center. OpenAlex indexes 116 publications with 799 citations (h-index 11).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1145 Olentangy River Rd Fl 3
Columbus, OH 432123117
Telephone
614-293-5066Provider last certified this registry record 28 Feb 2024.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20241 payment
- Gilead Sciences, Inc.Program year20221 payment
- AstraZeneca Pharmaceuticals LPProgram year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
86.2%Aromatase Inhibitor61%Anastrozole67%Letrozole33%Part D≥30 patientsKinase inhibitor18.2%Kisqali100%Part D<11 patients+ 1 more class in this area
Nervous system
13.8%Phenothiazine6.9%Prochlorperazine Maleate100%Part D<11 patientsOpioid Agonist6.9%Oxycodone Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Adverse events in patients treated with neoadjuvant chemo/immunotherapy for triple negative breast cancer: results from seven academic medical centers
Breast Cancer Research and Treatment
2025 - BRD4 inhibition leads to MDSC apoptosis and enhances checkpoint blockade therapy
Journal of Clinical Investigation
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Ricardo Carrau, MD
The Ohio State University Comprehensive Cancer Center
Gregory Otterson, MD
The Ohio State University Comprehensive Cancer Center
Steven Clinton, MD, PhD
The Ohio State University Comprehensive Cancer Center
Christian Rolfo, MD
The Ohio State University Comprehensive Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”